Phase I Human Trial of F351 Initiated in China

China Patent and Trademark Office Grants Patent for F351,GNI's Key Therapeutic Product for Liver Disease

GNI Receives Patent Approval in China for Important Cancer Targets

GNI Researchers in China Identify Important New Regulator of Inflammation

The Documentary Channel STV broadcasted the TV series, "The Sky of Innovation", which focuses on Zhangjiang Hi-Tech Park. The TV series included an interview with Dr. Ying Luo and a description of the new drug development effort at Shanghai Gen

GNI Ranked Number Six in the 2007 Deloitte FAST 50

The China Economic Review published an article about the life sciences outsourcing industry in China. Interviews with Dr. Christopher Savoie, Chairman and CEO of GNI, and Dr. Ying Luo, President and CEO of Shanghai Genomics and COO of GNI, were

GNI Successfully Completes IPO

The Xinhua News Agency released a video script, entitled "Colloguing for the Development of Pharm-Valley in Zhangjiang", on its website. Dr. Ying Luo, President and CEO of Shanghai Genomics, was featured in the video.